Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.40 |
| ▸ | RAMP3 | O60896 | 4/20 | 0.40 |
| ▸ | CALCR | P30988 | 4/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | GRPR | P30550 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538867 | 1.00 | SLC15A2 (0.43) | SLC15A2GHSRIL23RBACE1VIPR1 | |
| SCHEMBL29774694 | 0.82 | SLC15A2 (0.52) | SLC15A2GHSRBACE1RAMP3CALCR | |
| SCHEMBL29774663 | 0.82 | SLC15A2 (0.52) | SLC15A2GHSRBACE1RAMP3CALCR | |
| SCHEMBL29391246 | 0.79 | SLC15A2 (0.56) | SLC15A2REN | |
| SCHEMBL27906686 | 0.79 | SLC15A2 (0.58) | SLC15A2REN | |
| SCHEMBL28806214 | 0.78 | CYP3A4 (0.59) | SLC15A2REN | |
| SCHEMBL29868096 | 0.77 | CYP3A4 (0.59) | SLC15A2 | |
| SCHEMBL21748180 | 0.77 | CYP3A4 (0.59) | SLC15A2 | |
| SCHEMBL29727567 | 0.76 | CYP3A4 (0.59) | SLC15A2 | |
| SCHEMBL27747542 | 0.76 | CYP3A4 (0.56) | SLC15A2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | disclosed |
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | SLC15A2 3567/4885GHSR 190/4885IL23R 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.